Cinclus Pharma

The composition of the Nomination Committee has now been established, and the company
today announces that the Nomination Committee for the 2026 Annual General Meeting consists
of the following members:
 
Bita Sehat, appointed by Trill Impact Ventures Pharma 1 AB (Chair of the Nomination Committee)
Karl Tobieson, appointed by Linc AB
Kjell Andersson, appointed by PetoMaj Invest AB
Lennart Hansson, Chairman of the Board, is an acting member of the Nomination Committee.

The shareholders who have appointed members to the Nomination Committee together represent approximately 17.4 percent of the votes in Cinclus Pharma Holding AB (publ) as of September 30, 2025.
 
Cinclus Pharma Holding AB (publ)’s Annual General Meeting will be held on Thursday May 21, 2026.
 
The Nomination Committee shall submit proposals for resolution by the 2026 Annual General Meeting pertaining to the election of Chairman of the Meeting, fees and composition of the Board, auditors’ fees and the election of auditors and, if necessary, proposals for changes in the instruction to the Nomination Committee. The Nomination Committee’s proposals will be presented in the Notice to the 2026 Annual General Meeting and on Cinclus Pharma’s website, www.cincluspharma.com.

Shareholders wishing to submit proposals to the Nomination Committee can do so by sending an e-mail to cincluspharma.valberedning@vinge.se (subject “Nomination Committee”) or by letter posted to Cinclus Pharma Holding AB (publ), Attn: CFO Maria Engström, Kungsbron 1, SE-111 22, Stockholm, Sweden.

Proposals should, in order to be timely assessed by the Nomination Committee, be submitted no later than February 28, 2026.